# Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

> **NCT05877859** · — · RECRUITING · sponsor: **Emory University** · enrollment: 10 (estimated)

## Conditions studied

- Breast Cancer Triple Negative
- Breast Cancer Stage II
- Breast Cancer Stage III
- Breast Cancer Invasive

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05877859
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-30
- **Primary completion:** 2027-02-20
- **Final completion:** 2028-02-20
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05877859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05877859, "Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT05877859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*